Beckman Coulter Inc. SYNCHRON Systems Barbiturates Reagent (BARB 1 X 250); Catalog No. 475012 - Product Usage: BARB reagent, in conjunction with UniCel DxC 600/800 System(s) and SYNCHRON Systems Drugs of Abuse Testing (DAT) Urine Calibrators, is intended for the qualitative determination of barbiturates in human urine at a cutoff value of 200 ng/mL The BARB assay provides a rapid screening procedure for determining the presence of barbiturates (BARB) and its metabolites in urine. Recall

Check Your Product

According to the U.S. Food and Drug Administration (FDA)

Reason for Recall

As stated by FDA

The firm has identified that cross-reactivity testing may not meet the claims indicated in the Barbiturates Reagent Chemistry Information Sheet (CIS). The presence of certain compounds in urine may result in false positive or false negative results.

Recommended Action

Per FDA guidance

On 06/12/2019, an Urgent Medical Device Recall Letter was sent to customers via first class mail and/or email informing them that the firm has identified, through study results, that cross-reactivity testing may not meet the claims indicated in the Barbiturates Chemistry Information Sheet (CIS). Customers were informed that the presence of the following compounds in urine may lead to false negative results: Barbital at a concentration of 1500 to ~1700 ng/mL; Butabarbital at a concentration of 250 to ~300 ng/mL; Butalbital at a concentration of 400 to ~500 ng/mL; Diallybarbital at a concentration of 600 to ~700 ng/mL; Pentobarbital at a concentration of 500 to ~600 ng/mL; Phenobarbital at a concentration of 800 to ~900 ng/mL; Talbutal at a concentration of 80 to ~125 ng/mL. Customers were also informed that the presence of Glutethimide in urine at a concentration of ~ 8 to 80 g/mL may lead to false positive results. Customers were instructed to discontinue use and discard all BARB reagent lots M903174 and older following their laboratory's disposal protocol. Customers were informed that negative results due to the differences between the claimed and actual cross reactivity concentrations are not clinically significant, and that per the current Chemistry Information Sheet for this product, the reporting of a positive result by this assay should be confirmed by another generally accepted nonimmunological method; therefore retrospective review of patient results is not required. Customers were requested to share this information with their laboratory staff and retain this recall notification as part of their laboratory Quality System documentation. If customers forwarded any of the affected product listed to another laboratory, they were requested to provide that laboratory a copy of Urgent Recall Notification Letter. Customers were requested to respond to Beckman Coulter within 10 days, electronically if the customer received the notification by email; or manu